Distemper, Cav-2, Parvovirus 2B

Verify with FDA CVM →

11 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
11
Total Reports
2
Deaths Reported
1820.0%
Death Rate

Active Ingredients

Distemper, Cav-2, Parvovirus 2B

Administration Routes

UnknownSubcutaneous

Species Affected

Dog 11

Most Affected Breeds

Retriever - Golden 1
Retriever - Labrador 1
Shepherd Dog - German 1
Chihuahua 1
Terrier (unspecified) 1
Cattle Dog - Australian (blue heeler, red heeler, Queensland cattledog) 1
Bulldog - American 1
Pointing Dog - German Short-haired 1
Dog (other) 1
Terrier - Bull - Staffordshire 1

Most Reported Reactions

Facial swelling (see also 'Skin') 3
Lethargy (see also Central nervous system depression in 'Neurological') 3
Diarrhoea 3
Vomiting 2
Seizure NOS 2
Erythema (for urticaria see Immune SOC) 1
Decreased appetite 1
Depression 1
Low platelet count 1
Leucopenia NOS 1
Elevated serum alkaline phosphatase (SAP) 1
Elevated cholesterol (total) 1

Outcome Breakdown

Ongoing
7 (63.6%)
Recovered/Normal
1 (9.1%)
Died
1 (9.1%)
Euthanized
1 (9.1%)
Outcome Unknown
1 (9.1%)

Data Summary

Metric Value
Total adverse event reports 11
Reports involving death 2
Case-fatality rate (reported events) 1820.0%
Distinct species in reports 1
Distinct breeds in reports 11
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Distemper, Cav-2, Parvovirus 2B Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 11 adverse event reports referencing Distemper, Cav-2, Parvovirus 2B, including 2 reports in which the animal died — a 1820.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Distemper, Cav-2, Parvovirus 2B. Reported administration routes include Unknown, Subcutaneous. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Distemper, Cav-2, Parvovirus 2B reports are Dog (11 reports), with Dog accounting for the largest share. Within those species, Retriever - Golden (1), Retriever - Labrador (1), Shepherd Dog - German (1) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Distemper, Cav-2, Parvovirus 2B are Facial swelling (see also 'Skin') (3), Lethargy (see also Central nervous system depression in 'Neurological') (3), Diarrhoea (3), Vomiting (2). Of the 11 reports with a coded outcome, Ongoing is the leading category at 63.6%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Distemper, Cav-2, Parvovirus 2B.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial